Hello, and welcome to the fourth quarter and full year report 2023. My name is Caroline, and I'll be your coordinator for today's event. Please note, this call is being recorded, and for the duration of the call, your lines will be on listen-only mode. However, you'll have an opportunity to ask questions at the end of the call. This can be done by pressing star one on your telephone keypad to register your questions. If you require assistance at any point, please press star zero, and you'll be connected to an operator. I will now hand over the call to your host, Mr. Patrik Tolf, to begin today's conference. Thank you. Thank you. Good morning, and welcome to the earnings call for the fourth quarter and full year 2023. Time is now 10:00 A.M., and the date is the second of February, 2024. My name is Patrik Tolf, and I am the CFO for the Vitrolife Group. I will now hand over the call to our CEO, Bronwyn Brophy. Thank you, Patrik. Good morning, everyone, and thank you for joining. If I can now move you to the second page of the deck, we will start with the highlights for quarter four. As you can see, we have delivered improved margins, both gross and EBITDA, with gross margin increasing 2.7 percentage points versus the same quarter last year, and EBITDA margins of 32.5%. This, in the case of the EBITDA margins, is mainly attributable to product and market mix. We had a fantastic quarter in our technologies business. In fact, it was the highest quarter ever, with double-digit growth across the regions and very robust growth in two of our key strategic markets, namely the U.S. and China. Then, as most of you will be aware, we launched our new corporate strategy at our Capital Markets Day that we hosted in Stockholm in December, where we set out our new corporate strategy, the five key strategic pillars that we believe will help us to drive long-term, sustainable, profitable growth for our company, and we also updated our long-term financial objectives. I will now move you to the next slide, please, where we will look at the key metrics and also take a look at the performance in the full year. Sales for the quarter of SEK 904 million, that's an increase in SEK of 6%, but in organic growth in local currencies, that is a growth of 5%. I've already spoken about margin and EBITDA. You will also see that our operating cash flow increased to SEK 171 million for the quarter. If we look then at the full year, we see sales of SEK 3.512 million. That is a 10% increase in SEK versus the previous year, and 5% organic growth in local currencies. Our EBITDA performance, similar in terms of percentage, versus 2022, so SEK 1.136 million on EBITDA, delivering the margin of 32.3%. And our operating cash flow for the year went up from SEK 636 million to SEK 757 million. Earnings per share also increasing. Just to give you then the full year performance in local currencies in terms of our three business areas, consumable performance for the year in local currencies was 9%, technologies 11%, and genetic services, excluding discounted business, -1%. So that is the performance by business area for the full year. I will now move you to the next slide, and we will look at sales and growth per geographical segment in local currencies. So let's start with the Americas, and it's important to bear in mind here that Americas includes both North and South America. Organic growth in the Americas was -5% in the quarter. We had a very strong performance in technologies, but the overall growth of the region was impacted by a decline in genetic services, most notably in the ERA test. I would like to highlight that the performance of ERA in North America does appear to be stabilizing, but versus the previous quarter last year, of course, it did have an impact. EMEA performance for the quarter, plus 6%. We had double-digit growth in technologies, despite the fact that Europe does have higher penetration rates for our time-lapse EmbryoScope. ERA was also impacted in the EMEA region, but the volume of ERA testing and the revenue contribution is less material, and we also moved more rapidly here with our remediation plan. I think as well across the genetic services, we do see nice growth in some of our other tests, and we saw solid growth across the consumables portfolio in the EMEA region. APAC, 16% growth, a fantastic performance across the portfolio, especially in China, which is a key market for us. China delivered triple-digit growth, off an increasingly large base, in technology, so really, really nice to see this. But it's not just a story about China. India and other key large markets in the region are also doing very, very well. So very strong performance in APAC. And then if we look at the contribution by region, we do see a healthy split with, of course, 32% of the share of total sales coming from Americas, 38% from EMEA, and 30% from APAC. And I think with that substantial growth and sustainable and consistent growth that we're seeing in APAC, we would expect that contribution to increase going forward. I'll then move you to the next slide, and we will move into looking at our sales by business area. So our core consumables business performed well, with media doing particularly well, double-digit growth in APAC, and above-market growth in most of our key markets. Media business is, of course, very central to the success of Vitrolife Group, and, and we have increasing market shares in most of our main markets. However, our genomics kitted business was impacted by substantial stocking up in the first half of the year, while customers transitioned to our new EmbryoMap technology. And probably, really the best way to explain this phenomenon is actually to look at the bar charts. You'll see that in the first quarter and in the second quarter of 2023, they were particularly strong in consumables. It was strong across the board, media and disposable devices, but the performance of our kitted business was standout, and we do see the impact of that stocking prior to customers transitioning. Just to give you some figures, Genomics increased, Genomics kitted business increased 21% in quarter two and 15% in quarter one. What I would say is that in the final month of the year, in December, we did start to see customers ordering. So it appears that that transition and phasing should be leveling out. North America was the region that suffered most from this kitted impact. But aside from that, good performance, as I said, across core consumables and most notably in media. I will now move you to the next slide, where we will cover genetic services business area. Total growth for the quarter in local currencies was -2%. Americas, again, North and South, declined due to the ERA impact. So ERA declined 20% in the quarter versus the same quarter last year, and that PGT-A insourcing that we mentioned in the first and second quarters of 2023 still going through our numbers. So it will be the end of quarter one, beginning of quarter two, before we get a clean base in comparison there. Aside from that, we did see growth across the rest of the portfolio in genetic services, so it's good to see the diversification of the revenue into some of our non-invasive and newly launched tests. EMEA, interestingly, 6% growth in EMEA. EMEA was also impacted by ERA, as I previously mentioned, but it is a less material proportion. We have executed on our remediation plans, and we did see good growth in some of the other tests in the genetic services portfolio in EMEA. And then APAC, 16% growth for the quarter. Very strong growth in some of the key markets. I'd like to call out India, which is doing very, very well, and, you know, the base there is becoming material. So, you know, good performance in APAC, I would say robust performance in EMEA. Americas, we are addressing, of course, the decline in ERA, but we do see that leveling out month-on-month. And then finally, if I can move you to the technologies business area. Look, this was a fantastic quarter. It was our largest revenue ever. You can see there, 206, double growth in all regions, so 31% growth in local currencies, 13% in EMEA. This is a great performance in a market that's more penetrated for time-lapse, especially Western Europe. APAC growth of 37%. China is doing very, very well. Triple-digit growth in two of our key markets, so U.S. and China, as I said. And I think what's also a very healthy sign in this business is we're seeing some nice traction in terms of the consumable revenue and technologies, and also the service revenue. Americas, great to see traction on time-lapse in the U.S. I think our customers there are really starting to see the benefits of the workflow efficiency that EmbryoScope brings to the very heart of the clinic. So, it is off a lower base, but nonetheless, it's good to see us getting traction in North America. So I think the other point I'd like to highlight before handing over to Patrik is, we did set out on our capital markets day, the importance of these two markets to us. And of course, time-lapse and technologies is a key cornerstone in terms of owning the platform, strategic pillar. So good to see that we are starting to get some nice traction in those two critical markets. So with that, I will hand over to Patrik. Thank you, Bronwyn. And then we will move back then to our reporting segment. So if I ask you please then to change to the next slide, where you then see our reporting segments, down to market contribution and also then contribution margin. If you then look on the sales, as Bronwyn have just explained, you see the growth in sales for the various regions. You also then see how we have distributed then the gross income. The 56.9% is then distributed then with the highest gross margin within APAC, and then ranging down to Americas. This obviously then follows our product mix. It also is impacted then by the sales volume per region. Then we take out the direct selling expenses that we have per region. Excuse me, and that brings us down to our market contribution. You can then see that we are continuing then to increase the market contribution in APAC and also in EMEA, but we are slightly lower than following the decline in revenues for the Americas market region. Moving on to the next slide, where we then look on the Q4 financial highlights. We see that the net sales for the Vitrolife Group for the fourth quarter has increased with 6%, and that is in SEK, and the currency impact for this quarter has been relatively small compared to other quarters, so that is approximately then 1% unit. We then move down to the gross income, and the gross income then increased to SEK 514 million, giving us an EBIT, no, sorry, a gross margin of 56.9%. And that is driven then by higher sales of core consumables and also technologies that is driving the margin improvement. We are also, as we have talked about, excuse me, in previous calls and previous quarters, driven by the operational excellence programs, particularly then within Genetic Services, and that also has a positive impact. All in all, this brings us down then to an EBITDA of SEK 294 million with a margin of 32.5%. So all in all, we see that the net sales are increasing 6%. We also see that the gross income is increasing substantially higher, with 11%, and EBITDA is growing with 6.5%. So moving on then to the OpEx, which you will see on the next slide. You can see that the operating expenses for the fourth quarter has increased by 12%. And the largest increase, as you see, is within our selling expenses, and that is then related then to continuous investments in the commercial scale-up in high potential market activities. We have administrative expenses approximately on the same level, although that we had a couple of one-timers for the fourth quarter. We also then continue to increase our investments in R&D to continue to accelerate the time to market of the new products that we have in the pipeline. Generally, you can also say that we have slight higher traveling costs, and that impacts particularly when it comes to the selling expenses. Moving on then to the next slide, where you will see an income that is then adjusted for the non-cash impairment charge that we did and announced here on the press release on the twenty-third of January. And here you will then find the quarter and the full year, and how that is adjusted then for the non-cash impairment charge. And as you, as you know, we book this one as other operating expenses of SEK 4.3 billion. Now you can see then how this is then distributed then on the net income down to SEK 121 million for the quarter, and the equivalent number is then SEK 449 million for the full year. So hopefully that gives you a bit clarity on how we have accounted then for the non-cash impairment charge. And consequently, of course, this has an impact on the balance sheet with decline in goodwill and also a decline in equity. To summarize, I move to the next slide, which then are the key financials. And again, just to repeat on the quarter, SEK 904 million of sales, gross margin 56.9%, and EBITDA of SEK 294 million, giving us then an EBITDA margin of 32.5%. On the full year basis, you can see that we continue then to, of course, continue to grow the net revenue, which is then a 10% increase in SEK, if you then exclude the discontinued business. Including that one, the sales increase is 9%. We continue then to, again, increase the gross margin, EBITDA margin of 1,136. Keep in mind also, as we have been stating in the report, that we have, during 2023, had non-recurring costs of approximately SEK 25 million, which is primarily driven then by CEO succession and warranty provisions that we did during the first and second quarter, which actually means that we are running at a higher EBITDA margin throughout the year. Moving on to earnings per share, we continue to increase that one, so that's now 3.31 earnings per share. We continue then to generate good operating cash flow, which brings down then the net debt to EBITDA, where we are now down to 1. And also, also then saw in our communication and in the report, the board proposed that we increase the dividend from 85 öre per share up to SEK 1 per share. So with those words, I leave it back to you, Bronwyn. Thank you, Patrik. If we can move to the next slide. This is hopefully a slide that is starting to become familiar. And I really wanted to talk through this slide again, because this is the roadmap for the Vitrolife Group. This is what we believe we need to execute on in order to drive sustainable, profitable growth for our company. I think it's very important that I highlight that we will be tracking progress in terms of our ability to execute and hit the key milestones in relation to this plan. Just to summarize it again, for everybody, the market trends that we see and we expect to see going forward, growth and demand for this market. Cycle growth is expected to be somewhere between 5%-7%, but as access and affordability increases, we would expect these rates to increase. There is a labor and a skills shortage at all levels of this industry, hence the need for increased digitalization and automation in the labs. And again, this is something that we believe we can bring to our customers. Consolidation is happening. It appeared to slow down at points in time, but the general trend is towards consolidation. If we take the U.S. as an example, 50% of all U.S. clinics are now part of a chain. Regionalization, what do we mean by that? We tend to see a larger amount of genetic testing in terms of the number of cycles performed in the U.S. versus other regions, although that is starting to change. I think you've seen from the numbers that we've presented today, genetics testing is starting to increase in areas like Asia and also certain countries in Europe. Then patient empowerment. This is nothing specific to our industry that's happening across healthcare. Our vision is obviously to enable people to fulfill the dream of having a healthy baby, and our mission is to be the global leading partner in reproductive health. We also want to strive for better treatment outcomes for patients. The long-term growth and financial targets that we highlighted, annual organic revenue growth in local currencies above 10%, EBITDA margin north of 33%, and net debt to EBITDA less than 3, and then our five key strategic pillars. So what you should be seeing reflected in the numbers is based on the execution and progress towards these five pillars, and it is number one, own the platform, connecting products and services. This is why we are pleased to see the traction that Technologies is getting in our key markets. Innovate to expand leadership. We have a great pipeline. We need to accelerate the rate at which we bring products and tests to market. The pipeline is only as good as the ability to commercialize, so we think we have quite an opportunity there. Accelerating key markets. Look, you know, there, all of our markets are important to us, but we believe our greatest opportunities lie in the U.S. and China, and I think it's important that we focus and double down in those key geographies where we have opportunities to develop the market and take share. Optimizing our go-to-market model. This is important in terms of how we go to market, how we tell our story, and how we leverage the full breadth of the Vitrolife portfolio. And then, very importantly, driving operational excellence across the company so that we can fund this journey. And to that end, we have brought in some specialist talent to help us with these programs across all business areas, regions, and functions. So then my final slide before we open up for questions and answers. Going forward, what are we going to be executing on in the nearer term? Optimizing our go-to-market model. We need more feet on the street, and we need to pare back in terms of back office. Scaling up in the U.S. That has already started, but we need to accelerate there, and the opportunities in the U.S., we're all very familiar with. We're doing very well in consumables, media in particular. We believe we have opportunities to increase our share in core consumables. We have very good momentum, but I think we have opportunities to do even better. We have high quality, high quality media, and because of the investments that we've made in capacity, we are able to satisfy that demand when we do take share. Accelerating penetration of time-lapse. Globally, this is unique in terms of our portfolio. I think it's great to see this happening, but we need to make sure that it continues to happen. Then we have some great opportunities in terms of genetic services outside of PGT-A. Our more differentiated tests, our non-invasive tests, we are starting to see this revenue pick up, and we have an opportunity to accelerate. I'd like to thank you for listening to us, and we will now be able to open up to questions. Yes. We leave it over to the moderator. Sure. Thank you. If you would like to ask a question, please signal by pressing star one on your telephone keypad. We will take the first question from line, Ulrik Trattner from Carnegie. The line is open now. Please go ahead. Great. Thank you very much and good morning. A few questions on my end. I'm starting off with consumables, and you mentioned genetic test kits and the phasing from old products into new, but how worried should we be in terms of the underlying market in the U.S.? And can you give us some indication how much consumable X genetic kits were growing for Q4? Yeah. So good morning, Ulrik, and thank you for the question. We don't believe you should be worried. It is clearly a phasing impact. We can see the stocking effect in quarter one and quarter two. I don't want to come across as complacent. We want all of our business areas to be growing in all quarters, but the stocking effect is clear as we drill down into the numbers. I do think it was good and a healthy sign to see that in the month of December, some of those customers who hadn't ordered in a number of months were starting to place orders with us again. We're also, you know, confident, and we've had very good feedback from our key customers in terms of our new EmbryoMap. So, we, you know, I don't think it should be, you know, cause for concern. We're confident in terms of our ability to transition our key customers over to EmbryoMap. Aside from that, you know, core consumables is doing well. You know, very strong media performance in APAC, good growth in EMEA, Middle East and Turkey, double-digit growth, double-digit growth, UK, Ireland. I'm not gonna give you every number, Ulrik, but you know, looking at the- Yeah. Looking at the breakdown here, t here shouldn't be any cause for concern in terms of the core consumables business of Vitrolife. Okay, great. Thank you. And on technology, obviously, great performance and obviously great to see technologies and time-lapse growing in the U.S. Are you feeling any difference in terms of sentiment and adoption? And you talked about workflow efficiency, but is it something that has triggered this ramp-up in sales that you think is sustainable? And I also note that your selling expenses for the U.S. market is increasing by 25% year-on-year. Is there something related to that, or how should we sort of view this entire shift in sales for the U.S. market? Yeah. So I can start, maybe Patrik, and then if you want to add some color. So thank you for the question, Ulrik. Great question. I believe there are a number of factors contributing to the acceleration in technologies. I think one of them is focus, okay? So really doubling down in terms of a technology that is unique to the Vitrolife Group, that, that's one. We did increase our investment in both China and the U.S. in terms of capital sales specialists. I think in China, that's starting to pay dividends. In the U.S., should pay increasing dividends going forward in terms of, in terms of revenue. I think the other key thing is we have, very much focused on, on time-lapse in terms of embryo evaluation and iDAScore, and that is clearly a very compelling part of the value proposition. Where we've probably focused less in the past is on workflow efficiency. Now, we have tailored our message to highlight the benefits of workflow efficiency, and we have customers for, you know, for example, Cornell and, our, our largest time-lapse customer in San Francisco, UCSF, they are clearly seeing the workflow benefits. So I, I think the workflow benefits, the, the true magnitude of that is starting to be realized by our customers, and I think that's also probably propelling and boosting the sales. So I would say three-dimensional, focus, the increased investments that we've made, and then, Patrik, I'm, I'm not sure if you want to add anything- No Additional to that. No, I think you covered it. Great. But it's. Maybe, Ulrik, if I could just add one other point. Excuse me, I should add. The pipeline for time-lapse orders is very good for this quarter and for the coming quarters. So we don't believe this is a flash in the pan, that, you know, that the order book looks very good. Great. And I note that you... Well, two parts here. You sound very forward-leaning for 2024, taking market shares, and the obvious question would be, in which areas and geographies you're seeing taking market share. As well as, you sound a little bit more upbeat on China. Is there do you see the trend of China opening up and as well, India, new market, it's a growing IVF market, how substantial is the sales contribution? Okay, well, I'll start, Patrik. Yeah. Okay. Sorry, Ulrik, I'm taking all your questions here. I'm hogging the floor. So where can we take share? I think we can take share in consumables. We have a very high quality portfolio, great reputation, and, you know, good share, but there's always ability to take more, okay? This is, relatively speaking, still a fragmented market. So I think we have great opportunity to take share in media, in disposable devices. Technologies, that's more about, you know, a market development play. And I think in genetic services, we have a lot of opportunities in terms of our non-invasive tests to really start driving the penetration of those tests. China. You know, China's a really interesting one because I think we've been challenged in the past in terms of how sustainable is your growth in China. You know, all our leading indicators are looking very good on China. We're not reliant on... Even though we've had an outstanding performance in technologies, it's across the portfolio. So we're not overly reliant on any one business, on any one business area. And, you know, the demand is not just holding up, it's accelerating. So again, EMEA is looking very strong in quarter one. Order book is looking good on time-lapse. So, we're feeling pretty good about China. I think that's fair to say, Patrik. And then India, yeah, I mean, great point that, that you make, Ulrik. India, sometimes China steals the light from India, but, you know, I have to say here. In terms of its total contribution, it's becoming increasingly material, as part of our APAC region. Good growth, double-digit growth in the quarter across the board. Very nice performance in genetic services, very good performance in disposable devices. So, I think we have opportunities in India to drive further penetration in that market, and clearly going to be a very large market and important market going forward. I don't know, Patrik, if this- It sums it up very well. Okay. I'm stealing all of Patrik's. Perhaps you can answer the follow-up question then on India. India, obviously a very fast-growing market. Yeah. But it's also been a low-cost market. But when I look at your market contribution for Q4 for APAC, it looks quite good, and it's actually up sequentially. So how just can you help us with the dynamic of your sales in India, if it is margin dilutive, or if you can keep up with the margins and then just expand in India? It's not margin dilutive. Of course, I mean, as Bronwyn said, I mean, the relative share of India still are relatively low, but increasing quite nicely here, as you say, right? And as I say, yes, it's compared to other markets, it's a relatively low-cost market. So, and also, you really need to be present in India in order to do successful business in India as well. We are getting there. We are making progress in various areas, and it is definitely contributing to our margins for the region. I think maybe the final point that I would add, Ulrik, and it's a similar case in China. Very good local team on the ground. So I think India is similar to China in that regard. You know, Indian people who know the market, know the customers, clinic set up, I, I think that's really, really important, as opposed to placing a, you know, more Western lens on, on the Indian market. I think that's one of the key success factors for both India and China for, for the Vitrolife Group. Great. Last question on my end, relating to ERA, and I think it's perhaps more fair to compare it on a sequential basis. Are you? You mentioned stabilization, but even for the U.S. market, are you seeing flat or growing sales for ERA sequentially, or even if you have month-by-month comparisons, what are you currently seeing? I can start with that one. Flat. It's flat. The decline has halted. It's not yet in growth trajectory, but we are pleased to see the stabilization. You know, it did take a sharp decline, so it's stabilizing at the moment. And I do think that is in large part down to our remediation efforts. We are, as you know, doing additional clinical work in order to be able to support that study. That's going to take time, but for the moment, it's stabilization. We're not yet in positive trajectory on ERA in North America. Okay, great. Thanks for answering the questions. I'll get back into the queue. Thank you. Thank you, Ulrik. Thank you. We will take the next question from line, [Susanna Quagmuno from SHB]. The line is open now. Please go ahead. Hello. Thank you for taking my questions. I wanted to start, first of all, just to double down on the consumables and the genomics kit. Could you give us an update on the deal that you made with Illumina in 2018? I think it's up for re-review in 2023, and how that factors into this new dynamic in consumables. Hi, Susanna. Yes, I mean, as you know, we signed an agreement with Illumina a couple of years ago, and that was extended during the last year. So, that in essence means that we all continue to sell those kits as well. So that does not really have any impact on this one. Basically now it's also moving into the next generation, moving into the EmbryoMap as we have been speaking about. So, that agreement is still in place there, and we are now changing the kit for the half year during 2023. Okay. And then I also wanted to ask something about your operational excellence program, specifically in terms of consumables. Is it fair to assume that you're reaching a maximum capacity in terms of media manufacturing? I noted that one of your ambitions from the CMD was to double your capacity. So, how is Vitrolife planning on doing this? And specifically with regards to culture media, and how will you take market share? And then as a follow-up, with the market share that you say you have a chance of taking more, is that down to one of your larger competitors having issues with quality? If I start with the first point that you're making here now as well, I mean, yes, we are continuously investing into our manufacturing capacity, for our media. You know, also that we have increased our capacity then also for medical devices. And we are also making new investments and have done so during the fourth quarter here as well to increase the capacity for the media production. So, we are ready to continue to increase volume with continuous high quality, which is a key essence and is key aspect that we are very known for, and that's something that we continue to focus on here as well. So from a production capacity perspective, we have more capabilities to increase our manufacturing of media. Yeah, maybe if I could jump in there. Thank you for the question, Susanna. And so we, we have been working on, even prior to me joining the company, our, our media footprint, our capacity, our site master plans, in order to be able to deliver on our ability to take share or execute on our ability to take share. So, so capacity, not a concern. Where do we believe we can take share across all markets? I, I, I think China is a really good example in terms of what we were able to do, with competitor exits there. You know, certain competitors facing challenges right now, it happens to all companies at, at different points in time. But of course, it is an opportunity for us, to convert some of those customers to our media in, in North America, and, you know, across the globe. So, you know, our, our media, it's synonymous with quality. We have very vigorous quality and test protocols, as, as do most companies. But, you know, as, as we look at that part of the portfolio, speak to customers, our reputation on, on media is, is excellent, it builds a lot of confidence. So I think that's something that we can leverage, and it's an opportunity to take share. Okay, great. Just one final follow-up. Should we expect low single digit consumable growth in H1, 2024? The very honest answer to that question is, Susanna, I would be disappointed if we were delivering low single digits on consumables in the coming quarters. So can't make any promises, you know, but we typically don't issue guidance, but that would certainly not be the aim. This is a core part of our company. We're doubling down. We believe we have opportunities to take share. You know, if we're growing double digit in key markets, then we need to keep that trend going. Great. Thank you. You're welcome. Okay, we'll take the next question from Sten Gustafsson from ABG Sundal Collier. The line is open now, please go ahead. Thank you. Good morning. Thanks for taking my questions. Perhaps we could start with the PGT-A test and the insourcing you talked about last year. If you could provide us with an update, if that has increased or decreased in the U.S. Yeah, let's start with that one. Yeah. So, thank you for the question. PGT-A insourcing has not increased in the U.S., so we were clearly impacted by this in quarter two of 2023, and it impacted the numbers throughout the year, but we have not suffered from additional insourcing of PGT-A. I would actually say aside or adjusting for, not this, that's not a way of making excuses, but adjusting for the insourcing of that large chain, the business is actually growing quite healthy. So we haven't seen that insourcing trend increase and have not been impacted by it. Excellent. Thank you. My second question relates to transportation costs. Given the turmoil on the Red Sea and the freight rates going up, how should we think about this for 2024? Will there be much higher costs for you? And how will this play out in terms of delayed shipments or supply constraints or something like that? Thank you. It's a good question, and that's obviously something that we are working on here as well. We have seen some impact of that one during the fourth quarter, as well. I mentioned travel costs, that's one side, but that's obviously more traveling of our personnel rather than our goods. But of course, it has an impact, and that's obviously something, a challenge that we are addressing now for 2024. But if anything, we see that there is a cost increase and a cost pressure for the logistics side. Absolutely so. And we will obviously try to offset that one, work in a different way, but it has definitely an impact for us during 2024. Would it be possible to try to quantify it in some way, or is that- It's a relatively small portion of our costs. But of course, it adds up for the group when it comes to all the logistics, given also that we are operating and selling into globally about 125 markets. But it's not a substantial impact on the cost line. Okay. Thank you. My last question relates to the outlook for 2024, and maybe you don't wanna provide us with numbers here, but is it fair to assume that given the fact that you sound rather upbeat and talk about gaining market share, et cetera. At the same time, you have, at least in the near term, some headwinds on genetic services in the U.S. But is it fair to assume that you're probably gonna grow faster than the overall market this year, i.e., above 5%-7%? So I can take that one, Patrik. So we definitely want to grow above market and expect to grow above market in consumables. Same applies to technologies. We do have headwinds in genetic services. We are addressing those headwinds. But absolutely, our aim always is to grow above market rates. So we don't like to make promises that we can't deliver on, but we are certainly aiming as a company and taking all actions necessary to increase our growth rates. And of course, for us, the goal has to be that we are growing faster than the cycle growth in the market. We need to be growing faster than cycle growth. Perfect. Thank you very much. Congratulations on a great quarter. Thank you. Thank you very much. Thank you. Thank you for the question. We will take the next question from line, Johan Unnérus from Rede ye. The line is open now. Please go ahead. Great, thanks. I start off with some follow-up, and especially related to genetic services. You had -10% organic growth, which was better than Q3 at -50%, more in line with Q2. What to expect here looking into 2024? You're talking about improving, fading headwind. Can you reach positive organic growth by mid-year? Thank you for the question. Yeah, so a couple of factors at play here. So, we are seeing ERA stabilization in North America, so that is good, given the situation that we had earlier in the year. But ERA is still declining outside of the U.S., so we do see ERA declining in EMEA. The impact is lessened because the revenue simply isn't as material as it was in North America. But we do need to navigate that ERA decline OUS. The PGT-A phenomenon that ends kind of midway or early quarter two, so that certainly helps in terms of baseline comparisons. We are starting to see increase in revenue in some of the other tests outside of ERA and PGT-A. That's good to see. But the revenue contribution of those tests is small, comparatively speaking. So we really do have to sort of move the needle in PGT-A, in order to be able to shift the overall performance of genetic services. But we are certainly aiming to move ourselves into slightly more positive territory in terms of performance of the overall business area. I think the fact that APAC is doing well and EMEA is also performing pretty solidly, it's really all about America. That is the one that has the biggest revenue contribution and is also the region that suffered most in terms of ERA. So, a few dynamics here for us to navigate and manage, but also some positive green shoots in terms of ability to get things going in a more positive direction. So it sounds like it should be achievable to maybe hit positive growth by somewhere around midyear. To add some granularity or caveat, it seems like Q1 last year was pretty healthy on genetic services, and the PGT-A headwind will remain in Q1, so maybe we should have modest expectations for this quarter. Yeah. I would say for this quarter, best to have modest expectations. Yeah. Yeah. Yes. That's- But improving as Improving as the year progresses. Mm. Yeah. And on the growth for it? Yeah, and Johan, also, as you know, Johan, I mean, if you look on the, on the ERA, the big decline in ERA started in, in the second quarter, 2023, as well. Yeah. And on the growth margin, which was obviously very positive and also despite the mix, where you had a very good support from technology, it can be viewed in different ways, I suppose. One way of looking at it, it is that on a more normal consumable contribution quarter, that suggests that the growth margin could take a further step up, or should we think view it like there's less of a difference between technology and consumable? The Consumables business is running on the highest gross margin, so absolutely so. But, I mean, the product mix, of course, when you look on the consolidated numbers, will of course always have an impact on the consolidated gross margin. We are, of course, continuing to, as we have talked about several times, when it comes to operational excellence, we are working on that side to manage the cost side as well. So, w e are taking actions to continue then to maintain the EBIT margins and obviously also then the gross margins that we are currently having. Yes. And finally, a reminder on the OpEx and especially the sales efforts on the capital markets. They were pretty clear that you had great ambitions, especially in the U.S. and also in China, and Q4 confirms this. What should we think about the step up in terms of OpEx commercial investment, put it that way, for the full year? Is it, should we expect something in line with Q4, delta, or can it go, move up further? Thank you for the question. We need to ramp up in the U.S., and U.S. scale-ups, I have done a few of them, they don't come cheap. So that's not if you have the growth ambitions that we have. And you know, if you look at our commercial footprint vis-à-vis our competitors, Vitrolife Group is not going to win if we don't scale up. So we have to take some calculated risks there, but we are confident in our ability to execute. That said, we do see ability to take out cost in some of our back-office functions, which I would argue are a little bit on the heavy side. So I do think, you know, that we should be able to fund the majority of that scale-up by taking out cost in other areas. We're gonna have to monitor it extremely closely. It's one of our key metrics in our dashboard. You know, so, the selling expenses will go up, admin expenses will be coming down. That's how we're going to fund this. And R&D expenses will also be going up. This is part of our own, the platform. It's intentional. We are ramping up, scaling up, and we want to accelerate some of the developments that we have in the pipeline, which really help to feed into this platform play, which we think is most definitely the way to go for the company. Thank you. Yes, it will. It's, of course, it's partly challenging to find- Yeah ... additional sales capacity, but it's also very important to monitor and make sure that you, they contribute and deliver. What's your experience from that side? Do you have a good track record in recruiting and follow-up? I do. And in my several previous slides, my most recent, in fact, based out of Uppsala, we did do a U.S. scale-up there. You know, access to talent in the U.S., it's a very tight labor market. I was watching CNBC this morning, and the labor market is very tight in the U.S, and getting good commercial talent in med tech and life science is definitely challenging. That said, I think we have a very good reputation. I had a discussion with a U.S. customer recently, and they—I won't name the other competitor, but they said: "If this competitor is Coca-Cola, you're Pepsi." So we maybe we need to start- Maybe we need to start leveraging that. So we have a, we have a great brand. We've really, really good products, synonymous with quality. EmbryoScope is really starting to gain traction. So we need to leverage that strong corporate brand to attract talent. And the best commercial talent in this space, it, it is expensive, but it's also the talent that, that delivers on growth. So, we, you know, we're very much focusing on this right now. I'm taking a personal interest in, in the recruitment and ensuring that we get the very best people. And then your, your point is an excellent one. You know, those, those individuals then need to deliver. The good thing about the U.S. is that notice periods tend to be shorter, so you're able to get the talent, once you identify the right talent, able to get it on board quicker. Great. Thank you. Even I don't like Coke or Pepsi. Neither do I. I stick with my, my Päron Swedish water, which I love. Uh-huh. Yeah. Excellent. Okay. Thank you. Thank you. Thank you. Thank you very much. Thank you. We will take the last question from line, Jakob Lembke from SEB. The line is open now. Please go ahead. Hi, and good morning. Firstly, on China, I mean, you seem to be quite upbeat about China today. My sense of things has been that maybe the recovery has been a bit slower than one initially would have hoped for. So what are you seeing in China? Is it sort of accelerating? Yeah, your thoughts on that. Yes. So thanks for the question, Jakob. Yeah, again, the, you know, overall China sentiment, I guess, is mixed. Some med device, med tech companies a little bit challenged. We are not experiencing that. We have double-digit growth in China, and it's not in the teens, okay? It's very strong. We have growth across the board, really nice on media. It's everywhere. So a very, very strong performance. I think market factors, Jakob, are important to consider here. I mean, the China birth rate has fallen dramatically. Policymakers, payers, you know, the establishment has to really step in here to support the IVF industry. So we are seeing better payment and coverage and support for couples embarking on the IVF journey and taking the decision to undergo IVF treatment. So I, you know, it's a very large market with a declining birth rate, with payment and coverage increasing. So I think we can continue to remain to be optimistic around China. And then I really have to acknowledge, in the case of Vitrolife Group, we have a fantastic team on the ground. So the opportunity is there, but maybe to the previous caller's question, ability to execute. Ability to execute is here with our team. So good market, you know, robust underlying demand, very strong leading indicators, and a team that's executing very, very well. So we remain optimistic on China, and as I said, order book is looking good, not just on time- lapse, but across the board. So we are not feeling any negative effects, and certainly seeing in our area full recovery. Yeah. Yes. I don't know, Patrik, is there something you would add there? No, I think, Yeah. I mean, as we have talked about, throughout the quarter here as well, that we have seen that the recovery would, you know, out of COVID, right, always start out of the consumables products, which it has done, and then later on comes the technologies business. And that we have seen now happening during the fourth quarter as well. And we have been delivering as much as we can and have had ability to, and the pipeline for 2024 looks very good as well. We've increased our commercial footprint in China. So we have put more feet on the street in China as well. Yeah. Okay. And then, just to follow up on the quality issues that your main competitor, I'm wondering if you've sort of seen any inflow of business from that as of yet? Yeah, so look, as I previously mentioned, it happens in companies. It happens in all companies, of course. And I suppose as an industry, you know, we don't wish that on competitors. What we want to do is what's in the best interest of customers and patients. We have seen some increases, you know, maybe I think we're only just really starting to see the start of that. It's just something that we will be monitoring closely, and it is an opportunity, of course. It is an opportunity, most notably in North America. But I wouldn't say we're seeing, you know, significant influx right now. No. Okay, and then on the- I think maybe... Yeah, maybe if I could add one point. I'm thinking out loud here, but there is a logic. You know, and it takes time to validate media, so changing media. This is a good thing for the Vitrolife Group, right? Media is a sticky product. Okay? Customers start using a media. They like us, they trust us, it's validated. So, you know, switching media takes a little bit more time than one might initially think. Okay. And then on genetic services, I mean, seeing as it sounds like the insourcing is maybe easing, I'm wondering a bit on the PGT-A test. I mean, do you see that you are gonna be able to get back to sort of more growth in the U.S. in 2024, maybe more towards the sort of market growth for that? Yeah, good question. I can take it, Patrik. Yeah, yeah. Sorry I'm- Yeah. Yeah, that's good. There you go. I'm stealing all the questions from Patrik. Yeah, so adjusting for the insourcing factor, which as I mentioned, starts to peter out mid-quarter two, you know, PGT-A is doing well. We have got some new customer gains there in the U.S. So, you know, certainly an opportunity to start driving it into higher growth levels. I don't know if there's something else to add, Patrik. Well, I mean, maybe we can just add, I mean, but as you know, during ESHRE this summer, we also then launched the Smart PGT-A Plus, and we started to sell that one during the, well, fourth quarter, really, on that side. So now we have additional product capabilities as well, which definitely then strengthens our ability to continue then to be successful in U.S. and other markets as well. Okay, and my final question was gonna be on the PGT-A Plus. I mean, is there any sort of financial impact from that as of Q4, and what do you expect for 2024? I wouldn't say that it has had any significant impact during the fourth quarter. Still, volume-wise, relatively low. But as time goes on here, we are expecting to see additional growth on Smart PGT-A Plus. That comes at a higher price, so that's obviously good for the bottom line. So but currently at a relatively small volume, but we are seeing positive momentum in that one, and in particular in U.S. Okay, very clear. That's all from me. Thank you very much. Thank you. Thank you. There's no further question at this time. I'll hand it back over to your host for closing remarks. Thank you. Thank you very much. Thank you for everybody for dialing in. Thank you for the great questions. Very much appreciated, and have a very nice weekend from all at the Vitrolife Group. Thank you. Bye-bye. Thank you for joining today's call. You may now disconnect.